After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...